Viragen Reports Continued U.S. Army Studies of Multiferon(R); Research Marks Next Step Toward Determining Biodefense Potential

May 31, 2006, 01:00 ET from Viragen, Inc.

    PLANTATION, Fla., May 31 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex:  
 VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC
 Bulletin Board: VGNI), today reported that the U.S. Army Medical Research
 Institute of Infectious Diseases (USAMRIID) has agreed to commence with a
 new series of in vivo studies (nonhuman primate models) to further
 determine the potential of Multiferon(R) (multi-subtype, natural human
 alpha interferon) as a potent, broad-acting anti-viral product capable of
 fighting certain "Category A" pathogens, a class of highly virulent viral
 threats, which have the potential to be used in biowarfare.
     "It is critical we identify products that can provide rapid medical
 defenses for a variety of potentially catastrophic viral threats, including
 viral hemorrhagic fevers such as Marburg and Ebola, both of which result in
 enormously high mortality rates," stated Lisa E. Hensley, Research Team
 Leader at USAMRIID. "Our initial in vitro evaluation studies showed that
 Multiferon(R) successfully demonstrated a protective effect on healthy
 cells subjected to these deadly infectious pathogens. USAMRIID's new series
 of studies are designed to expand upon the preliminary results by analyzing
 the effect of the drug in in vivo models that are very similar to human
 settings, making them a good indicator of the drug's broad-acting
 anti-viral properties in human use."
     "Through collaborative studies with USAMRIID and other biodefense
 research organizations, we are gathering evidence from independent sources
 in a cost- effective manner to position Multiferon(R) as a potential
 defense against unknown infectious agents when no vaccine exists, and/or be
 able to enhance the efficacy of vaccines. We look forward to these study
 results in the coming months," said Viragen's President & CEO, Charles A.
     Mr. Rice added that, in Multiferon(R), Viragen is delivering a highly
 innovative product that continues to demonstrate that all alpha interferons
 are not alike. "With a unique naturally glycosylated mixture of six alpha
 subtypes produced via our proprietary, patented manufacturing process,
 Viragen continues to collect data that supports new indications for
 Multiferon(R) beyond our European malignant melanoma strategy."
     To review the Category A, B & C Priority Pathogens as listed by the
 National Institute of Allergy and Infectious Diseases (NIAID), please
     While Viragen is not yet prepared to recommend Multiferon(R) as a
 prophylactic, preventive or treatment for any biodefense application,
 continued mounting scientific evidence will confirm or refute the Company's
 belief that Multiferon(R) shows immuno-protective and anti-viral activity
 against multiple viral targets, and holds the potential to be more
 effective than other anti-viral products.
     About USAMRIID:
     USAMRIID, located at Fort Detrick, Maryland, is the lead medical
 research laboratory for the U.S. Biological Defense Research Program, and
 plays a key role in national defense and in infectious disease research.
 The Institute's mission is to conduct basic and applied research on
 biological threats resulting in medical solutions (such as vaccines, drugs
 and diagnostics) to protect the warfighter. USAMRIID is a subordinate
 laboratory of the U.S. Army Medical Research and Materiel Command.
     The information contained in this press release does not necessarily
 reflect the position or the policy of the U.S. Government and no official
 endorsement should be inferred.
     About Viragen, Inc.:
     With global operations in the U.S., Scotland and Sweden, Viragen is a
 biotechnology company engaged in the research, development, manufacture and
 commercialization of pharmaceutical proteins for the treatment of viral
 diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
 subtype, natural human alpha interferon) targeting a broad range of
 infectious and malignant diseases; and humanized monoclonal antibodies
 targeting specific antigens over-expressed on many types of cancers. We are
 also pioneering the development of Avian Transgenic Technology, with the
 renowned Roslin Institute, as a revolutionary manufacturing platform for
 the large-scale, efficient and economical production of human therapeutic
 proteins and antibodies.
           For more information, please visit:
      Viragen, Inc. Corporate Contact:
      Douglas Calder, Director of Communications
      Phone: (954) 233-8746; Fax: (954) 233-1414
     The foregoing press announcement contains forward-looking statements
 that can be identified by such terminology such as "believes," "expects,"
 "potential," "plans," "suggests," "may," "should," "could," "intends," or
 similar expressions. Such forward-looking statements involve known and
 unknown risks, uncertainties and other factors that may cause the actual
 results to be materially different from any future results, performance or
 achievements expressed or implied by such statements. In particular,
 management's expectations regarding future research, development and/or
 commercial results could be affected by, among other things, uncertainties
 relating to clinical trials and product development; availability of future
 financing; unexpected regulatory delays or government regulation generally;
 the Company's ability to obtain or maintain patent and other proprietary
 intellectual property protection; and competition in general.
 Forward-looking statements speak only as to the date they are made. The
 Company does not undertake to update forward-looking statements to reflect
 circumstances or events that occur after the date the forward-looking
 statements are made.

SOURCE Viragen, Inc.